KRAS Status Doesn’t Impact Treatment with 5-FU Alone

While researchers have found that colorectal cancer tumors that have mutated KRAS genes don’t respond to treatment with EFGR inhibitors Erbitux®(cetuximab) and Vectibix™(panitumumab), is the same thing true for other drugs?

5-FU (fluorouracil) is the backbone of most colorectal cancer treatment, given alone or in combination with other drugs.  What does KRAS status mean when 5-FU is the only treatment? Continue reading…

Posted by Kate Murphy on August 2nd, 2008
Posted in: Research & Treatment News | No Comments »
Tags: 5-FU, KRAS, survival benefit

KRAS Mutation Status Predicts Response to Erbitux in Canadian Study

Another study has shown that colon or rectal cancer patients whose tumors have mutated KRAS don’t benefit from Erbitux® (cetuximab).  However, in the study when only patients with normal or wild-type KRAS were considered, survival time almost doubled after treatment with Erbitux began. Continue reading…

Posted by Kate Murphy on July 1st, 2008
Posted in: Research & Treatment News | 2 Comments »
Tags: Erbitux, KRAS, metastatic colorectal cancer, survival benefit